Cardiol Therapeutics Inc.
NASDAQ:CRDLDrug Manufacturers - Specialty & Generic
-$0.01 today
- Market cap
- $114.64M
- Beta
- 0.80
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.31M
Average 0.68M
CRDL Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Cardiol Therapeutics Inc.NASDAQ: CRDL
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of CA$4.74M rose 2.1% year over year, ahead of the -9.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 9.9% from the prior quarter. Over 3 fiscal years it compounded at +7.3% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of CA$80.08M (+296.5%) for the fiscal year ending Dec 2026, a step up from the -22.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- CA$4.74M-9.9% QoQ
- Last fiscal yearDec 2025
- CA$20.2M-22.0% YoY
- LTMMar 2026
- CA$20.29M-9.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
CAD · from the income statement
- Latest · FY2025
- 20.2M CAD
- Year-over-year change
- -22.0%
- 4-year CAGR
- -2.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.2M | -22.0% |
| FY2024 | 2024-12-31 | 25.89M | +124.1% |
| FY2023 | 2023-12-31 | 11.55M | -29.3% |
| FY2022 | 2022-12-31 | 16.34M | -25.2% |
| FY2021 | 2021-12-31 | 21.86M | — |
Selling, General & Admin vs competitors
How CRDL compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -9.6% is the 7th highest of 10, against a peer median of -2.2%.
- Over three fiscal years its annual growth of +7.3% compares with a peer median of +7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2025 | ₪104.96M ILS | +12.9% | -6.2% | 43.2% | |
| LTM Mar 2026 | $66.32M USD | -15.5% | +12.7% | 64.9% | |
| LTM Mar 2026 | $26.33M USD | -2.2% | -17.3% | 171.8% | |
IMAImageneBio Inc | LTM Mar 2026 | $21.2M USD | -9.1% | -2.3% | — |
| FY2025 | $20.34M USD | +5.8% | -0.8% | 31781.3% | |
| LTM Mar 2026 | CA$20.29M CAD | -9.6% | +7.3% | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $15.32M USD | -41.8% | +90.0% | — |
| LTM Mar 2026 | €14.24M EUR | -27.6% | +7.0% | 48538.7% | |
| LTM Mar 2026 | $9.71M USD | +81.8% | +13.9% | 9251.4% | |
| LTM Mar 2026 | $9.52M USD | +9.5% | +20.6% | — | |
| Peer median (excluding CRDL) | — | -2.2% | +7.0% | 4711.6% | |
Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 62.27K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 174.26K | 162.23K | 187.38K | 0 | 0 |
| Gross Profit | (112K) | (162.23K) | (187.38K) | 0 | 0 |
| Gross Margin | -179.9% | — | — | — | — |
| Research & Development | 8.59M | 13.99M | 10.73M | 14.01M | 14.02M |
| Selling, General & Admin | 21.86M | 16.34M | 11.55M | 25.89M | 20.2M |
| Operating Expenses | 30.46M | 30.33M | 22.29M | 40.28M | 34.32M |
| Depreciation & Amortization | 174.26K | 162.23K | 187.38K | 162.11K | 101.98K |
| EBITDA | (24.84M) | (22.66M) | (21.04M) | (36.52M) | (33.72M) |
| EBITDA Margin | -39891.0% | — | — | — | — |
| Operating Income | (30.57M) | (30.49M) | (22.47M) | (40.28M) | (34.32M) |
| Operating Margin | -49092.4% | — | — | — | — |
| Interest Income | 106K | 1.24M | 2.04M | 1.19M | 726.4K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.56M | 7.68M | 1.25M | 3.6M | 497.42K |
| Income Before Tax | (25.01M) | (22.82M) | (21.22M) | (36.68M) | (33.82M) |
| Pre-Tax Margin | -40170.9% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (25.01M) | (22.82M) | (21.22M) | (36.68M) | (33.82M) |
| Net Margin | -40170.9% | — | — | — | — |
| EPS (Basic) | (0.73) | (0.49) | (0.44) | (0.51) | (0.39) |
| EPS (Diluted) | (0.73) | (0.49) | (0.44) | (0.51) | (0.39) |
| Weighted Avg Shares | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
| Weighted Avg Shares (Diluted) | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
Cardiol Therapeutics Inc.
NASDAQ:CRDL
Intrinsic Alpha fair value
Locked
Current Price
$0.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.